These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 16899108)

  • 21. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis.
    Choy EHS; Calabrese LH
    Rheumatology (Oxford); 2018 Nov; 57(11):1885-1895. PubMed ID: 29186541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic uses of anti-interleukin-6 receptor antibody.
    Kang S; Tanaka T; Kishimoto T
    Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers.
    Ho LJ; Luo SF; Lai JH
    Biochem Pharmacol; 2015 Sep; 97(1):16-26. PubMed ID: 26080005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticytokine therapy in autoimmune diseases.
    Nishimoto N; Kishimoto T; Yoshizaki K
    Intern Med; 1999 Feb; 38(2):178-82. PubMed ID: 10225680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Actual status of antiinterleukin-1 therapies in rheumatic diseases.
    Geyer M; Müller-Ladner U
    Curr Opin Rheumatol; 2010 May; 22(3):246-51. PubMed ID: 20150813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials.
    Kavanaugh A
    Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S16-20. PubMed ID: 17708740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
    Nishimoto N
    Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action.
    Bayry J; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
    Nat Clin Pract Rheumatol; 2007 May; 3(5):262-72. PubMed ID: 17471245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling.
    Hoge J; Yan I; Jänner N; Schumacher V; Chalaris A; Steinmetz OM; Engel DR; Scheller J; Rose-John S; Mittrücker HW
    J Immunol; 2013 Jan; 190(2):703-11. PubMed ID: 23241882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-6 inhibition--tolerability profile and clinical implications.
    Strand V; Yazici Y
    Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S21-4. PubMed ID: 17708741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel immunological targets in rheumatic diseases: clues from current therapies.
    D'Acquisto F; Rattazzi L; Piras G; Galuppo ML
    Drug Discov Today; 2014 Aug; 19(8):1155-60. PubMed ID: 24984284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential Binding of Sarilumab and Tocilizumab to IL-6Rα and Effects of Receptor Occupancy on Clinical Parameters.
    Xu C; Rafique A; Potocky T; Paccaly A; Nolain P; Lu Q; Iglesias-Rodriguez M; St John G; Nivens MC; Kanamaluru V; Fairhurst J; Ishii T; Maldonado R; Choy E; Emery P
    J Clin Pharmacol; 2021 May; 61(5):714-724. PubMed ID: 33314148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The biology and medical implications of interleukin-6.
    Tanaka T; Kishimoto T
    Cancer Immunol Res; 2014 Apr; 2(4):288-94. PubMed ID: 24764575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review.
    Jung JY; Kim MY; Suh CH; Kim HA
    Pediatr Rheumatol Online J; 2018 Dec; 16(1):79. PubMed ID: 30547812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-6: a new therapeutic target.
    Smolen JS; Maini RN
    Arthritis Res Ther; 2006; 8 Suppl 2(Suppl 2):S5. PubMed ID: 16899109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.
    Mees ST; Toellner S; Marx K; Faendrich F; Kallen KJ; Schroeder J; Haier J; Kahlke V
    J Surg Res; 2009 Dec; 157(2):235-42. PubMed ID: 19589542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tocilizumab in pediatric rheumatology: the clinical experience.
    Gurion R; Singer NG
    Curr Rheumatol Rep; 2013 Jul; 15(7):338. PubMed ID: 23715975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
    Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T
    Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
    Rose-John S; Scheller J; Elson G; Jones SA
    J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.